Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk Plans Value-based Contracts For GLP-1 Agonist Ozempic

Executive Summary

Company aims to shift gradually away from once-daily GLP-1 Victoza (liraglutide) toward once-weekly Ozempic (semaglutide).

You may also be interested in...



Novo Anticipates Q4 Soft Launch For Closely Watched Oral GLP-1 Agent Rybelsus In The US

US CMO Todd Hobbs told Scrip the full launch will be in early 2020 as sales, manufacturing and reimbursement preparations for oral semaglutide continue based on the now-approved FDA label in type 2 diabetes.

In Conversation With Novo Nordisk CMO: The Ongoing Fight Against Diabetes

Stephen Gough has kept his connections with Oxford University and will see collaborations between the two expand next month with the opening of the Novo Nordisk Research Centre Oxford. The executive spoke to Scrip.

Novo Nordisk Touts First-Line Potential For Oral Semaglutide

Novo's oral GLP-1 receptor agonist has a lot going for it in diabetes based on the latest data, but still needs to prove cardiovascular benefit; a new large outcomes study is now in the works.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel